{"transactions":[{"id":747617,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-05T20:19:07.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":1.6738,"value":418450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."}],"balance_after":1721298,"source":{"system":"sec-edgar","filing":"0001193125-26-259637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526259637/ownership.xml","form_type":"4"}},{"id":823974,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2026-03-31T20:17:57.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":632318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."}],"balance_after":632318,"derivative":{"underlying":"Common Stock","underlying_shares":632318},"source":{"system":"sec-edgar","filing":"0001193125-26-134631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526134631/ownership.xml","form_type":"4"}},{"id":823973,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-31T20:17:57.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":1880510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026."}],"balance_after":1880510,"derivative":{"exercise_price":1.77,"expiration_date":"2036-03-26","underlying":"Common Stock","underlying_shares":1880510},"source":{"system":"sec-edgar","filing":"0001193125-26-134631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526134631/ownership.xml","form_type":"4"}},{"id":964820,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:00:06.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.453,"underlying":"Common Stock","underlying_shares":1187},"source":{"system":"sec-edgar","filing":"0001193125-25-322639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322639/ownership.xml","form_type":"4"}},{"id":964819,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:00:06.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.45,"underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0001193125-25-322639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322639/ownership.xml","form_type":"4"}},{"id":964818,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:00:06.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1218,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":5.41,"underlying":"Common Stock","underlying_shares":1218},"source":{"system":"sec-edgar","filing":"0001193125-25-322639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322639/ownership.xml","form_type":"4"}},{"id":964817,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T16:00:06.000Z","date":"2025-12-16","kind":"other","planned":false,"acquired":false,"shares":27,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\" and together with Parent, the \"Purchasers\"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the \"Offer Price\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-322639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322639/ownership.xml","form_type":"4"}},{"id":1136925,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T17:00:29.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":8238,"derivative":{"exercise_price":3.453,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":1187},"source":{"system":"sec-edgar","filing":"0000950170-25-076441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017025076441/ownership.xml","form_type":"4"}},{"id":1219225,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T21:17:27.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":809710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025."}],"balance_after":809710,"derivative":{"exercise_price":6.17,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":809710},"source":{"system":"sec-edgar","filing":"0000950170-25-034674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025034674/ownership.xml","form_type":"4"}},{"id":1291753,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-29T16:30:07.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":5833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option shall vest one-third of the total number of shares each one-year period after the vesting commencement date, so that the option shall be fully vested on the third anniversary of the vesting commencement date, subject to the Holder's continued service to the Company through each such vesting date."}],"balance_after":5833,"derivative":{"exercise_price":4.45,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0000950170-25-010532","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017025010532/ownership.xml","form_type":"4"}},{"id":1501806,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T16:53:59.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":14625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":14625,"derivative":{"exercise_price":0.451,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":14625},"source":{"system":"sec-edgar","filing":"0000950170-24-064687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024064687/ownership.xml","form_type":"4"}},{"id":1580566,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-09","kind":"grant","planned":false,"acquired":true,"shares":1081201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024."}],"balance_after":1081201,"derivative":{"exercise_price":3.62,"expiration_date":"2034-03-08","underlying":"Common Stock","underlying_shares":1081201},"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1580565,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":85324,"price":3.05,"value":260238.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1471298,"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1580564,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":97914,"price":3.2735,"value":320521.479,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1556622,"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1783755,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":48021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":48021},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783754,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":32953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":32953},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783753,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":192084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":192084},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783752,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":73807,"price":7.22,"value":532886.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options."}],"balance_after":1654536,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783751,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":48021,"price":0.552,"value":26507.592,"ownership":{"direct":true},"balance_after":1728343,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783750,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":32953,"price":0.552,"value":18190.056,"ownership":{"direct":true},"balance_after":1680322,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783749,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":192084,"price":0.552,"value":106030.368,"ownership":{"direct":true},"balance_after":1647369,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1896612,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T16:44:03.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":14625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":14625,"derivative":{"exercise_price":2.12,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":14625},"source":{"system":"sec-edgar","filing":"0001209191-23-028784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919123028784/doc4.xml","form_type":"4"}},{"id":1960599,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":1.6,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960598,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":4.62,"expiration_date":"2029-07-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960597,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960596,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":14.27,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960595,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":10964,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":10.79,"expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":10964},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960594,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":9.05,"expiration_date":"2026-07-27","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960593,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960592,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:17:08.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1960591,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T09:17:08.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":15004,"price":7.12,"value":106828.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924323007663/doc4.xml","form_type":"4"}},{"id":1978910,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T21:22:33.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023."}],"balance_after":250000,"derivative":{"exercise_price":6.76,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-23-006742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924323006742/doc4.xml","form_type":"4"}},{"id":1978909,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-02T21:22:33.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":238750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":1455285,"source":{"system":"sec-edgar","filing":"0000899243-23-006742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924323006742/doc4.xml","form_type":"4"}},{"id":2205125,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2022-07-19T20:34:35.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":604308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."}],"balance_after":604308,"derivative":{"underlying":"Common Stock","underlying_shares":604308},"source":{"system":"sec-edgar","filing":"0000899243-22-026346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322026346/doc4.xml","form_type":"4"}},{"id":2220947,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-27T10:41:07.000Z","date":"2022-06-23","kind":"purchase","acquired":true,"shares":17700,"price":3.3642,"value":59546.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.3591 to $3.3693, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":1216535,"source":{"system":"sec-edgar","filing":"0000899243-22-024132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322024132/doc4.xml","form_type":"4"}},{"id":2223795,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-22T17:15:17.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919122038719/doc4.xml","form_type":"4"}},{"id":2288678,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-28T19:07:46.000Z","date":"2022-04-27","kind":"grant","acquired":true,"shares":57750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":57750,"derivative":{"exercise_price":0.66,"expiration_date":"2032-04-26","underlying":"Common Stock","underlying_shares":57750},"source":{"system":"sec-edgar","filing":"0001209191-22-026068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919122026068/doc4.xml","form_type":"4"}},{"id":2310883,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2022-04-01T23:44:04.000Z","date":"2022-03-30","kind":"grant","acquired":true,"shares":207758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52."}],"balance_after":207758,"derivative":{"exercise_price":4.52,"underlying":"Common Stock","underlying_shares":207758},"source":{"system":"sec-edgar","filing":"0000899243-22-013176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322013176/doc4.xml","form_type":"4"}},{"id":2310882,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-01T23:44:04.000Z","date":"2022-03-30","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022."}],"balance_after":250000,"derivative":{"exercise_price":4.52,"expiration_date":"2032-03-29","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-22-013176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322013176/doc4.xml","form_type":"4"}},{"id":2310881,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-01T23:44:04.000Z","date":"2022-03-30","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":1198835,"source":{"system":"sec-edgar","filing":"0000899243-22-013176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924322013176/doc4.xml","form_type":"4"}},{"id":2625817,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-23T18:15:32.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":57750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":57750,"derivative":{"exercise_price":1.55,"expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":57750},"source":{"system":"sec-edgar","filing":"0001209191-21-048017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919121048017/doc4.xml","form_type":"4"}},{"id":2678789,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-06-07T16:14:22.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 4, 2022, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-038568","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919121038568/doc4.xml","form_type":"4"}},{"id":2749392,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-14T23:23:43.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021."}],"balance_after":250000,"derivative":{"exercise_price":11.71,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-21-015837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924321015837/doc4.xml","form_type":"4"}},{"id":2749391,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-14T23:23:43.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":46619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":948835,"source":{"system":"sec-edgar","filing":"0000899243-21-015837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924321015837/doc4.xml","form_type":"4"}},{"id":2969447,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-11-23T11:17:06.000Z","date":"2020-11-19","kind":"other","acquired":false,"shares":2741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were called for redemption by the Issuer at their Black-Scholes value."}],"balance_after":0,"derivative":{"exercise_price":43.16,"exercise_date":"2017-05-24","expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":2741},"source":{"system":"sec-edgar","filing":"0000905718-20-001135","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000090571820001135/springbank_fm4nov192020.xml","form_type":"4"}},{"id":3018140,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-01T16:00:13.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":9235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":60016,"source":{"system":"sec-edgar","filing":"0001209191-20-052599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919120052599/doc4.xml","form_type":"4"}},{"id":3094857,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T16:00:25.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":8418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":50781,"source":{"system":"sec-edgar","filing":"0001209191-20-039703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919120039703/doc4.xml","form_type":"4"}},{"id":3099548,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T16:00:18.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":1.6,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-20-038877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919120038877/doc4.xml","form_type":"4"}},{"id":3130441,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-29T16:42:40.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":57750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":57750,"derivative":{"exercise_price":2.6,"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":57750},"source":{"system":"sec-edgar","filing":"0001209191-20-032964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919120032964/doc4.xml","form_type":"4"}},{"id":3188723,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T16:00:11.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":13306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":42363,"source":{"system":"sec-edgar","filing":"0001209191-20-022073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919120022073/doc4.xml","form_type":"4"}},{"id":3226813,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2020-03-05T00:44:05.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":450865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78."}],"balance_after":450865,"derivative":{"exercise_price":3.78,"underlying":"Common Stock","underlying_shares":450865},"source":{"system":"sec-edgar","filing":"0000899243-20-007060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/doc4.xml","form_type":"4"}},{"id":3226812,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-05T00:44:05.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020."}],"balance_after":250000,"derivative":{"exercise_price":3.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-20-007060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/doc4.xml","form_type":"4"}},{"id":3226811,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-05T00:44:05.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":902216,"source":{"system":"sec-edgar","filing":"0000899243-20-007060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/doc4.xml","form_type":"4"}},{"id":3326635,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-02T17:09:04.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":7832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":29057,"source":{"system":"sec-edgar","filing":"0001209191-20-000382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919120000382/doc4.xml","form_type":"4"}},{"id":3336414,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-18T12:35:31.000Z","date":"2019-12-16","kind":"purchase","acquired":true,"shares":20000,"price":5.0954,"value":101908.0,"ownership":{"direct":true},"balance_after":652216,"source":{"system":"sec-edgar","filing":"0000899243-19-029509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319029509/doc4.xml","form_type":"4"}},{"id":3400536,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-02T11:36:25.000Z","date":"2019-09-30","kind":"purchase","acquired":true,"shares":8710,"price":5.6812,"value":49483.252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchase of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.41 to $5.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":632216,"source":{"system":"sec-edgar","filing":"0000899243-19-024582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319024582/doc4.xml","form_type":"4"}},{"id":3402757,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-01T16:47:02.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":3597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":21225,"source":{"system":"sec-edgar","filing":"0001209191-19-051314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919119051314/doc4.xml","form_type":"4"}},{"id":3406203,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-25T11:40:13.000Z","date":"2019-09-23","kind":"purchase","acquired":true,"shares":8680,"price":5.8102,"value":50432.536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchase of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":623506,"source":{"system":"sec-edgar","filing":"0000899243-19-024225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319024225/doc4.xml","form_type":"4"}},{"id":3408811,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-20T11:37:40.000Z","date":"2019-09-18","kind":"purchase","acquired":true,"shares":14288,"price":5.9116,"value":84464.9408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.80 to $5.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":614826,"source":{"system":"sec-edgar","filing":"0000899243-19-023982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023982/doc4.xml","form_type":"4"}},{"id":3411906,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-17T20:21:02.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3000,"price":6.03,"value":18090.0,"ownership":{"direct":true},"balance_after":600538,"source":{"system":"sec-edgar","filing":"0000899243-19-023735","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023735/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-17"}},{"id":3411905,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-17T20:21:02.000Z","date":"2019-09-13","kind":"purchase","acquired":true,"shares":18547,"price":5.8963,"value":109358.6761,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 8,547 shares that were inadvertently omitted from the original Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.79 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":597538,"source":{"system":"sec-edgar","filing":"0000899243-19-023735","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023735/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-17"}},{"id":3411904,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-17T11:35:53.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":3000,"price":6.03,"value":18090.0,"ownership":{"direct":true},"balance_after":591991,"source":{"system":"sec-edgar","filing":"0000899243-19-023718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/doc4.xml","form_type":"4"}},{"id":3411903,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-17T11:35:53.000Z","date":"2019-09-13","kind":"purchase","acquired":true,"shares":10000,"price":5.79,"value":57900.0,"ownership":{"direct":true},"balance_after":588991,"source":{"system":"sec-edgar","filing":"0000899243-19-023718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/doc4.xml","form_type":"4"}},{"id":3417237,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-11T20:05:47.000Z","date":"2019-09-10","kind":"purchase","acquired":true,"shares":10000,"price":5.3937,"value":53937.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.375 to $5.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":578991,"source":{"system":"sec-edgar","filing":"0000899243-19-023317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/doc4.xml","form_type":"4"}},{"id":3417236,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-11T20:05:47.000Z","date":"2019-09-09","kind":"purchase","acquired":true,"shares":10000,"price":4.8887,"value":48887.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.88 to $4.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,937 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019."}],"balance_after":568991,"source":{"system":"sec-edgar","filing":"0000899243-19-023317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/doc4.xml","form_type":"4"}},{"id":3463409,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-11T08:55:10.000Z","date":"2019-07-10","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on July 10, 2019, the date of the Issuer's 2019 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":4.62,"expiration_date":"2029-07-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-041764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919119041764/doc4.xml","form_type":"4"}},{"id":3474350,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T09:00:54.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":3354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to receive shares in lieu of cash compensation for services as a director and committee member."}],"balance_after":17628,"source":{"system":"sec-edgar","filing":"0001209191-19-039565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919119039565/doc4.xml","form_type":"4"}},{"id":3539664,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-03T17:44:50.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/2/2020), subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":34000,"derivative":{"exercise_price":0.72,"expiration_date":"2029-05-01","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-19-027498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919119027498/doc4.xml","form_type":"4"}},{"id":3567568,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T16:03:48.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":1180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":14274,"source":{"system":"sec-edgar","filing":"0001209191-19-022335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919119022335/doc4.xml","form_type":"4"}},{"id":3605867,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2019-03-07T22:20:23.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":45329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05."}],"balance_after":45329,"derivative":{"exercise_price":8.05,"underlying":"Common Stock","underlying_shares":45329},"source":{"system":"sec-edgar","filing":"0000899243-19-006729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/doc4.xml","form_type":"4"}},{"id":3605866,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-07T22:20:23.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019."}],"balance_after":250000,"derivative":{"exercise_price":8.05,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-19-006729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/doc4.xml","form_type":"4"}},{"id":3605865,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-03-07T22:20:23.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,571 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2018."}],"balance_after":556054,"source":{"system":"sec-edgar","filing":"0000899243-19-006729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/doc4.xml","form_type":"4"}},{"id":3887918,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-19T16:28:18.000Z","date":"2018-06-18","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2018, the date of the Issuer's 2018 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":5500,"derivative":{"exercise_price":13.99,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-18-038560","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919118038560/doc4.xml","form_type":"4"}},{"id":3954883,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-27T16:22:58.000Z","date":"2018-04-26","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/26/2019), subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":34000,"derivative":{"exercise_price":2.36,"expiration_date":"2028-04-25","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-18-026570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919118026570/doc4.xml","form_type":"4"}},{"id":4005038,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-08T21:40:24.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":217293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018."}],"balance_after":217293,"derivative":{"exercise_price":8.6,"expiration_date":"2028-03-05","underlying":"Common Stock","underlying_shares":217293},"source":{"system":"sec-edgar","filing":"0000899243-18-006819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924318006819/doc4.xml","form_type":"4"}},{"id":4005037,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-08T21:40:24.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":101269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU).  The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 4,550 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017 and 575 shares of common stock acquired under the Issuer's ESPP in December 2017."}],"balance_after":302483,"source":{"system":"sec-edgar","filing":"0000899243-18-006819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924318006819/doc4.xml","form_type":"4"}},{"id":4110459,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T16:12:36.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":13094,"source":{"system":"sec-edgar","filing":"0001209191-18-000811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919118000811/doc4.xml","form_type":"4"}},{"id":4178305,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-30T22:03:52.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":15000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-058363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579179/000120919117058363/doc4.xml","form_type":"4"}},{"id":4193713,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-03T16:04:52.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":12242,"source":{"system":"sec-edgar","filing":"0001209191-17-054996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919117054996/doc4.xml","form_type":"4"}},{"id":4263298,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T16:08:55.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":11609,"source":{"system":"sec-edgar","filing":"0001209191-17-043254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919117043254/doc4.xml","form_type":"4"}},{"id":4278627,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-16T16:49:29.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 15, 2017, the date of the Issuer's 2017 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":5500,"derivative":{"exercise_price":14.27,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-17-040567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000120919117040567/doc4.xml","form_type":"4"}},{"id":4331579,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-05T17:58:41.000Z","date":"2017-05-03","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/3/2018), subject to the reporting person's continued service to the Issuer through such vesting date."}],"balance_after":34000,"derivative":{"exercise_price":2.72,"expiration_date":"2027-05-02","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-17-030425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000120919117030425/doc4.xml","form_type":"4"}},{"id":4396871,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-07T22:45:33.000Z","date":"2017-03-03","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017."}],"balance_after":250000,"derivative":{"exercise_price":5.1,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-17-006712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924317006712/doc4.xml","form_type":"4"}},{"id":4396870,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-07T22:45:33.000Z","date":"2017-03-03","kind":"grant","acquired":true,"shares":136806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU).  The RSU vests ratably in equal annual installments over a four-year period beginning on March 3, 2017, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":201214,"source":{"system":"sec-edgar","filing":"0000899243-17-006712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924317006712/doc4.xml","form_type":"4"}},{"id":4435529,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-21T21:32:54.000Z","date":"2017-02-17","kind":"purchase","acquired":true,"shares":22223,"price":4.5,"value":100003.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 17, 2017."}],"balance_after":64408,"source":{"system":"sec-edgar","filing":"0000899243-17-004754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000089924317004754/doc4.xml","form_type":"4"}},{"id":4542651,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2016-11-23T16:00:25.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":10964,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10964,"derivative":{"exercise_price":10.79,"exercise_date":"2017-05-24","expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":10964},"source":{"system":"sec-edgar","filing":"0000899243-16-034292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924316034292/doc4.xml","form_type":"4"}},{"id":4542650,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-23T16:00:25.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":10964,"price":9.12,"value":99991.68,"ownership":{"direct":true},"balance_after":10964,"source":{"system":"sec-edgar","filing":"0000899243-16-034292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566373/000089924316034292/doc4.xml","form_type":"4"}},{"id":4557145,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-14T23:15:41.000Z","date":"2016-11-09","kind":"exercise","acquired":true,"shares":28985,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one (1) share of the Issuer's common stock."}],"balance_after":153288,"source":{"system":"sec-edgar","filing":"0001214659-16-014637","document":"marketforms-36766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579179/000121465916014637/marketforms-36766.xml","form_type":"4"}},{"id":4557144,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2016-11-14T23:15:41.000Z","date":"2016-11-09","kind":"exercise","acquired":false,"shares":28985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's 2015 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one (1) share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering (\"IPO\"), subject to continued service through such event) and (b) time-based vesting restrictions (50% of the RSUs will satisfy the time-based vesting restrictions on each of the third and fourth anniversaries of July 11, 2013, subject to continued service through such dates). In addition, 100% of the RSUs will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event."}],"balance_after":28985,"source":{"system":"sec-edgar","filing":"0001214659-16-014637","document":"marketforms-36766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579179/000121465916014637/marketforms-36766.xml","form_type":"4"}}]}